There are currently 687 clinical trials in Orlando, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including AdventHealth Orlando, GSK Investigational Site, Orlando Clinical Research Center and Nemours Children's Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
CERENOVUS Neurothrombectomy Devices Registry
NCT05591183
Recruiting
A post-market registry evaluating the EmboTrap® Revascularization Device and CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter in acute ischemic stroke patients with confirmed intracranial large vessel occlusion.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/19/2022
Locations: Advent Health Orlando, Orlando, Florida
Conditions: Cerebral Stroke
Register for Updates
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
NCT03926624
Recruiting
Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6 mg/m²/day followed by a 14-day resting period per 28-day cycles. Control arm: Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens), dependin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/18/2022
Locations: AdventHealth Medical Group Blood and Marrow Transplant at Orlando, Orlando, Florida
Conditions: Leukemia, Myeloid, Acute
Register for Updates
Project Harmony 2.0: Relationship Education for Couples
NCT05587335
Recruiting
Project Harmony directly addresses prioritized areas identified by Administration of Children and Families, emphasizing healthy marriage promotion activities and career advancement opportunities for adults. Included in service provisions are elements of: [a] marriage and relationship education/skills, [b] marriage enhancement, [c] divorce reduction and [d] job and career advancement. The targeted service population for Project Harmony includes married/committed couples in the greater Orlando met... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/18/2022
Locations: University of Central Florida, Orlando, Florida
Conditions: Marital Relationship
Register for Updates
The Impact of a Human Breast Milk Supplement on Epigenetic and Cellular Markers
NCT05297097
Recruiting
This is a trial to assess the effects of the Trulacta supplement on biological age, sleep quality, immune system and wellness markers.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
09/07/2022
Locations: Central Florida Wellness, Orlando, Florida
Conditions: Aging
Register for Updates
Breast Cancer Liquid Biopsy Trial
NCT04962529
Recruiting
The purpose of this study is to continue to develop a liquid biopsy (minimally invasive blood test) that can be used to confirm if breast cancer has spread throughout the body and if this liquid biopsy test can provide comparable information to a highly invasive tissue biopsy. The knowledge gained in this study could be used in future studies to confirm cancer recurrence using a safe and minimally invasive procedure. The research will consist of looking for tumor cell(s) circulating in the blood... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/08/2022
Locations: 6555 Sanger Rd, Suite 260, Orlando, Florida
Conditions: Breast Cancer, Cancer
Register for Updates
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
NCT04857359
Recruiting
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.
Gender:
All
Ages:
Between 30 years and 85 years
Trial Updated:
05/18/2022
Locations: AES - DRS - Synexus Clinical Research US, Inc. - Orlando, Orlando, Florida
Conditions: Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Register for Updates
Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)
NCT04209543
Recruiting
This is a two-part study designed to evaluate the effect of Estetrol (E4) 15 or 20 mg, or placebo on the severity and frequency of vasomotor symptoms (VMS) (Efficacy Study Part) and the safety of E4 20 mg (Endometrial and General Safety Study Part)
Gender:
Female
Ages:
Between 40 years and 65 years
Trial Updated:
05/09/2022
Locations: Clinical Neurosciecne Solutions, Inc. dba CNS Healthcare, Orlando, Florida
Conditions: Vasomotor Symptoms, Menopausal Symptoms
Register for Updates
A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD
NCT04812262
Recruiting
This is a Phase 1, first in human (FiH), randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to investigate the safety, tolerability, PK and PD of DD01 administered by subcutaneous (SC) injection in overweight/obese subjects with type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD). The study will be conducted in 2 Parts (Part A and B), with up to 8 cohorts included in each part (Part A; Cohorts A1 to A8 and Part B; Co... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
05/03/2022
Locations: Combined Research Orlando, Orlando, Florida
Conditions: Overweight and Obesity, Type2 Diabetes, NAFLD
Register for Updates
The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes
NCT04753385
Recruiting
The objective of this study is to collect both active and passive data using a wearable, multi-sensor device (Verily Study Watch) and phone application (Mood App) which aims to capture mental health status, in subjects participating in the RECOVER clinical trial (A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/23/2022
Locations: APG Research, LLC, Orlando, Florida
Conditions: Treatment Resistant Depression
Register for Updates
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
NCT05211856
Recruiting
The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in subjects with previously untreated CLL.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
01/14/2022
Locations: Research Site, Orlando, Florida
Conditions: Chronic Lymphocytic Leukemia
Register for Updates
Low-Load Blood Flow Restriction on Patients With Multiple Sclerosis
NCT05177952
Recruiting
This research is being done to compare the current standard of care for strength training for patients with Multiple Sclerosis to lightweight resistance training with blood flow restriction.
Gender:
Female
Ages:
Between 18 years and 55 years
Trial Updated:
12/15/2021
Locations: University of Central Florida, Orlando, Florida
Conditions: Training Study, Multiple Sclerosis, Blood Flow Restriction
Register for Updates
Idylla EGFR Lung Trial
NCT04962191
Recruiting
This retrospective, observational study will compare the results of a BioCartis' EGFR mutation test on the Idylla platform with test results from SoC pathology results from tissue biopsies in the same setting. A comparable rapid testing platform for EGFR may serve as a more accessible means to diagnose, and overall, more patients treated successfully with targeted therapies. Up to 150 samples will be tested and compared with existing results.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/12/2021
Locations: 6555 Sanger Rd, Suite 260, Orlando, Florida
Conditions: Lung Cancer, Technology, Oncology
Register for Updates